ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,041 | +4.9% | 481 | 0.0% | 0.01% | +20.0% |
| Q2 2023 | $42,929 | -16.8% | 481 | 0.0% | 0.01% | -28.6% |
| Q1 2023 | $51,573 | -12.2% | 481 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $58,745 | +19.9% | 481 | 0.0% | 0.01% | -12.5% |
| Q3 2022 | $49,000 | -12.5% | 481 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $56,000 | -13.8% | 481 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $65,000 | -15.6% | 481 | 0.0% | 0.01% | -11.1% |
| Q3 2021 | $77,000 | -38.9% | 481 | -49.9% | 0.01% | -47.1% |
| Q2 2021 | $126,000 | +1.6% | 961 | 0.0% | 0.02% | -22.7% |
| Q1 2021 | $124,000 | -12.7% | 961 | 0.0% | 0.02% | -37.1% |
| Q2 2020 | $142,000 | +31.5% | 961 | 0.0% | 0.04% | +16.7% |
| Q1 2020 | $108,000 | -1.8% | 961 | 0.0% | 0.03% | +3.4% |
| Q2 2019 | $110,000 | -2.7% | 961 | 0.0% | 0.03% | -6.5% |
| Q1 2019 | $113,000 | – | 961 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |